Myclausen (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Myclausen, is an antimetabolite immunosuppressant presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection, treat lupus nephritis, and manage selected autoimmune diseases in adult patients.

GNH USA supplies Myclausen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to EU GMP standards and provides reliable global distribution for clinical and commercial needs.

Myclausen is an antimetabolite immunosuppressant used in conditions where immune modulation is required.

Organ transplant rejection: helps prevent immune‑mediated graft loss in kidney, heart, liver and other transplanted organs. Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus affecting the kidneys. Autoimmune diseases: suppresses abnormal immune activity in selected autoimmune disorders such as certain vasculitides.

Myclausen may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhoea. - Hematologic changes: leukopenia, anemia, thrombocytopenia. - Infections: increased susceptibility to bacterial, viral and fungal infections. - Headache and fatigue. - Elevated liver enzymes.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML). - Severe opportunistic infections such as cytomegalovirus disease. - Life‑threatening hypersensitivity reactions. - Renal impairment or acute kidney injury. - Malignancies, including lymphoproliferative disorders.

Before initiating Myclausen, clinicians should assess baseline laboratory values and monitor patients regularly.

Baseline labs: obtain complete blood count, liver and renal function tests. Infection risk: screen for latent viral infections (e.g., CMV, EBV) and vaccinate appropriately before therapy. Pregnancy: contraindicated; avoid use in women of childbearing potential unless effective contraception is used. Drug interactions: review concomitant medications for potential additive immunosuppression. Renal/hepatic impairment: adjust monitoring frequency in patients with organ dysfunction. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Myclausen can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Antimetabolites such as azathioprine: may cause excessive bone‑marrow suppression. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce mycophenolate exposure. - Live vaccines: increased risk of severe infection.

Moderate Interactions (Monitor Closely): - Antacids containing magnesium or aluminum: may decrease absorption; separate dosing by at least 2 hours. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Concomitant nephrotoxic agents (e.g., calcineurin inhibitors): watch for additive renal toxicity.